Hope for rare brain disease: patients get continued access to experimental drug
Disease control
AVAILABLE
This program offers ongoing access to the experimental drug ATH434 for people with multiple system atrophy (MSA), a rare and serious brain disorder. It is only for those who completed a previous Phase 2 study and whose doctor believes they may benefit. The goal is to provide cont…
Sponsor: Alterity Therapeutics • Aim: Disease control
Last updated May 04, 2026 00:44 UTC